By Counterforce Health Team in Oxbryta (voxelotor) —

Oxbryta (Voxelotor) Coverage by Aetna CVS Health in California: 2024 FDA Withdrawal and Your Treatment Options

Answer Box: Oxbryta (Voxelotor) Status and Next Steps

Oxbryta (voxelotor) was voluntarily withdrawn from all U.S. markets in September 2024 due to safety concerns. Aetna CVS Health and all insurers no longer authorize this medication. If you were taking Oxbryta, contact your hematologist immediately to discuss alternatives like hydroxyurea, L-glutamine, or crizanlizumab. For coverage denials of alternative treatments, California offers strong appeal rights through the Department of Managed Health Care (DMHC) Independent Medical Review process, with high overturn rates for specialty drug denials.

Immediate action needed: Schedule an urgent appointment with your sickle cell specialist to transition to approved alternatives.

Table of Contents

  1. Why Oxbryta Is No Longer Available
  2. Alternative Sickle Cell Treatments Covered by Aetna
  3. Aetna CVS Health Coverage Criteria for SCD Medications
  4. Step Therapy and Medical Exceptions
  5. Appeals Process: When Coverage Is Denied
  6. California's Independent Medical Review (IMR)
  7. Cost Support and Patient Assistance
  8. Frequently Asked Questions

Why Oxbryta Is No Longer Available

In September 2024, Pfizer voluntarily withdrew Oxbryta (voxelotor) from worldwide markets after clinical trials showed higher rates of vaso-occlusive crises and deaths compared to placebo. The FDA confirmed this withdrawal and advised all healthcare providers to stop prescribing the medication immediately.

Key Safety Findings:

  • Increased fatal events in clinical trials
  • Higher frequency of pain crises versus placebo
  • Benefits no longer outweighed risks for sickle cell disease patients
Critical: If you're currently taking Oxbryta, do not stop abruptly. Contact your hematologist within 24-48 hours to develop a safe transition plan, as sudden discontinuation can cause severe complications.

Alternative Sickle Cell Treatments Covered by Aetna

Aetna CVS Health covers several FDA-approved alternatives for sickle cell disease management:

Coverage at a Glance

Treatment Type Typical Coverage Prior Auth Required Formulary Tier
Hydroxyurea (Droxia, Siklos) Oral, first-line Standard coverage Usually no Tier 1-2
L-glutamine (Endari) Oral powder Covered with PA Yes Tier 3-4
Crizanlizumab (Adakveo) Injectable Specialty coverage Yes Specialty tier
Blood transfusions Hospital-based Medical necessity Case-by-case N/A
Gene therapy (Casgevy, Lyfgenia) One-time curative Highly restricted Yes Specialty

Sources: Aetna formulary guidelines and CVS Caremark coverage policies

Aetna CVS Health Coverage Criteria for SCD Medications

Medical Necessity Requirements

For specialty sickle cell treatments, Aetna typically requires:

  1. Confirmed diagnosis with appropriate ICD-10 codes (D57.x series)
  2. Documentation of disease severity (frequency of pain crises, hospitalizations)
  3. Prior therapy trials where clinically appropriate
  4. Prescriber specialty (hematology/oncology preferred)
  5. Clinical monitoring plan for safety and efficacy

Specific Criteria by Drug

L-glutamine (Endari):

  • Age 5 years or older
  • History of 2+ pain crises in previous 12 months
  • No contraindications to glutamine supplementation

Crizanlizumab (Adakveo):

  • Age 16 years or older
  • History of 2+ vaso-occlusive crises in previous 12 months
  • May be used with hydroxyurea
  • Requires specialty pharmacy dispensing

Step Therapy and Medical Exceptions

Standard Step Therapy Protocol

Aetna generally follows this treatment sequence:

  1. First-line: Hydroxyurea (unless contraindicated)
  2. Second-line: L-glutamine as add-on therapy
  3. Third-line: Crizanlizumab for refractory cases

Medical Exception Pathways

You can bypass step therapy if you provide documentation of:

  • Previous treatment failure with required first-line agents
  • Contraindications to step therapy medications
  • Intolerance with specific adverse events documented
  • Clinical urgency where delay would be harmful
Clinician Corner: When requesting medical exceptions, include specific details about prior treatments, duration of trials, reasons for discontinuation, and current clinical status. Reference FDA labeling and relevant ASH guidelines where applicable.

Appeals Process: When Coverage Is Denied

Aetna Internal Appeals Timeline

Appeal Level Deadline to File Decision Timeline Required Documents
Standard Appeal 180 days from denial 45 business days Appeal form, medical records, denial letter
Expedited Appeal 180 days from denial 72 hours Same as standard + urgency documentation
Peer-to-Peer Review Can request anytime Within 1 business day Clinical rationale, provider availability

Source: Aetna provider appeals process

Required Documentation for Appeals

Medical Necessity Letter Must Include:

  • Patient's complete diagnosis and ICD-10 codes
  • Detailed treatment history with dates and outcomes
  • Clinical rationale for requested medication
  • Literature support and guideline references
  • Monitoring plan and expected outcomes
  • Provider credentials and specialty

Supporting Records:

  • Recent clinic notes (within 30-60 days)
  • Laboratory results and imaging
  • Hospital discharge summaries
  • Documentation of treatment failures or contraindications

California's Independent Medical Review (IMR)

If Aetna upholds its denial after internal appeals, California residents can request an Independent Medical Review through the Department of Managed Health Care (DMHC).

IMR Success Rates for Specialty Drugs

Based on DMHC data, California has favorable overturn rates:

  • Medical necessity denials: 60-70% reversed
  • Experimental/investigational denials: 40-50% reversed
  • Specialty drug appeals: Often successful with proper documentation

How to File an IMR

  1. Complete internal appeals first (required in most cases)
  2. Submit IMR application within 6 months of final denial
  3. Provide comprehensive medical records and literature support
  4. DMHC reviews within 45 days (standard) or 14 days (expedited)
  5. Decision is binding on the insurance company
California Advantage: The IMR process is free to patients, and insurers must cover the cost of independent review. Contact the DMHC Help Center at (888) 466-2219 for assistance.

Cost Support and Patient Assistance

Manufacturer Programs

  • Novartis (Adakveo): Copay assistance and patient support programs
  • Emmaus (Endari): Patient assistance for eligible individuals
  • Check manufacturer websites for current eligibility and application processes

California-Specific Resources

  • Covered California premium subsidies for eligible individuals
  • Medi-Cal coverage for low-income residents
  • California Prescription Drug Discount Program for uninsured patients

Foundation Support

  • Patient Access Network Foundation (PAN)
  • HealthWell Foundation
  • National Organization for Rare Disorders (NORD)

Note: Eligibility and funding availability change frequently. Contact organizations directly for current status.

Frequently Asked Questions

Q: Can I still get Oxbryta through compassionate use or special programs? A: No. Pfizer has completely withdrawn Oxbryta from all markets, and compassionate use is not available. All patients must transition to alternative treatments.

Q: How long does Aetna take to decide prior authorization for sickle cell medications? A: Standard decisions typically take 45 business days, while expedited requests are decided within 72 hours when clinical urgency is documented.

Q: What if my doctor says I need a specific alternative but Aetna prefers a different one? A: Your physician can request a medical exception by documenting why the preferred alternative isn't suitable. Include contraindications, previous failures, or clinical factors that make the requested drug more appropriate.

Q: Does California have special protections for rare disease medications? A: Yes. California's IMR process provides strong external review rights, and the state has enacted step-therapy override laws that protect patients when delays could be harmful.

Q: Can I appeal if Aetna says my treatment is "experimental"? A: Absolutely. "Experimental/investigational" denials are frequently overturned in California IMR when FDA approval and clinical evidence support medical necessity.

Q: What happens if I can't afford my copay for specialty sickle cell drugs? A: Contact the drug manufacturer for copay assistance programs, apply for foundation grants, and ask your provider about free drug programs or clinical trials.

From Our Advocates

"We've seen many sickle cell patients successfully appeal specialty drug denials by providing comprehensive treatment histories and emphasizing the progressive nature of their disease. The key is documenting how current treatments aren't adequately controlling symptoms and why the requested medication is medically necessary. California's IMR process has been particularly effective for these cases when internal appeals fail."

For patients and healthcare providers navigating complex coverage decisions, Counterforce Health helps turn insurance denials into targeted, evidence-backed appeals. Our platform analyzes denial letters, identifies specific coverage criteria, and generates comprehensive appeals that address payer requirements with appropriate clinical evidence and regulatory citations.

Whether you're dealing with prior authorization requirements or appealing coverage denials, having the right documentation and understanding payer-specific workflows can significantly improve your chances of approval. Counterforce Health streamlines this process by providing templates and guidance tailored to your specific insurer and state regulations.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage policies change frequently, and individual circumstances vary. Always consult with your healthcare provider about treatment decisions and verify current coverage details with your insurance company. For assistance with appeals or coverage questions, contact the California Department of Managed Health Care at (888) 466-2219.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.